

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

NBL-S

RRID:CVCL_2136

Type: Cell Line

Proper Citation

RRID:CVCL_2136

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2136

Proper Citation: RRID:CVCL_2136

Description: Cell line NBL-S is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: [PMID:11550280](#), [PMID:15892104](#), [PMID:16822308](#), [PMID:18724359](#), [PMID:23202128](#), [PMID:28350380](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NBL-S

Synonyms: NBL_S, NBLS

Cross References: BioSample:SAMN03473469, Cosmic:848930, Cosmic:923829, Cosmic:930070, Cosmic:1019947, Cosmic:1109367, Cosmic:1161997, Cosmic:1167414, Cosmic:1526636, DSMZ:ACC-656, DSMZCellDive:ACC-656, GEO:GSM2371248, GEO:GSM2394377, GEO:GSM4104587, GEO:GSM4104588, GEO:GSM4105328, GEO:GSM4105329, GEO:GSM4105330, GEO:GSM4105331, GEO:GSM4105332, IARC_TP53:23593, Wikidata:Q54907552

ID: CVCL_2136

Record Creation Time: 20220427T220834+0000

Record Last Update: 20260905T181234+0000

Ratings and Alerts

No rating or validation information has been found for NBL-S.

No alerts have been found for NBL-S.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. *iScience*, 29(7), 116469.

Chaves GS, et al. (2026) Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma. *Clinical and translational science*, 19(3), e70508.

Lindsay J, et al. (2026) Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. *Molecular cancer therapeutics*, 25(4), 635.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. *Cancer research communications*, 5(1), 167.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. *Cancer discovery*, 15(10), 2054.

Graham MK, et al. (2024) The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. *Cancer research communications*, 4(6), 1533.

Kaufman ME, et al. (2024) Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures. *Cancer research communications*, 4(8), 2255.

Raman S, et al. (2021) A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. *Cell reports. Medicine*, 2(7), 100344.

Buongervino S, et al. (2021) Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. *Molecular cancer therapeutics*, 20(11), 2228.

Morita K, et al. (2020) Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. *Cell*, 181(3), 702.

Jung M, et al. (2020) ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. *International journal of cancer*, 147(8), 2225.